Poland’s Ryvu To Feed Galapagos’ R&D Effort
New Drug Target For Anti-inflammatories Identified
Executive Summary
Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos.
You may also be interested in...
Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Galapagos Sells CRO To Selvita For €31.2m
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.